Table 1.
Patient and [18F]PSMA-1007-PET/CT characteristics
| Characteristics | Value | Total number of available observations | |
|---|---|---|---|
| Age (years) | 175 | ||
| Mean ± SDa | 69 ± 8.8 | ||
| Median (range) | 70 (46–88) | ||
| Neoadjuvant treatment | 13 | 9.5% | 137 |
| Primary treatment | 137 | ||
| Radical prostatectomy | 107 | 78% | |
| EBRTb | 12 | 8.8% | |
| Androgen deprivation therapy | 10 | 7.3% | |
| Brachytherapy | 7 | 5.1% | |
| High Intensity Focused Ultrasound | 1 | 0.7% | |
| Adjuvant external beam radiation therapy | 30 | 22% | 137 |
| Prior androgen deprivation therapy | 83 | 61% | 137 |
| Ongoing androgen deprivation therapy | 42 | 24% | 175 |
| Salvage therapy | 137 | ||
| No salvage surgery or EBRT | 76 | 55% | |
| Salvage surgery | 13 | 9.5% | |
| EBRT | 39 | 28% | |
| Salvage surgery and EBRT | 9 | 6.6% | |
| Pathologic primary tumour staging | 107 | ||
| pT2 | 44 | 41% | |
| pT3 | 60 | 56% | |
| pT4 | 3 | 2.8% | |
| Pathologic regional lymph node staging | 79 | ||
| pN0 | 57 | 72% | |
| pN1 | 22 | 28% | |
| Positive surgical margin at radical prostatectomy | 41 | 41% | 101 |
| Number of positive lymph nodes removed at primary treatment | 78 | ||
| Median (range) | 0 (0–18) | ||
| Gleason score | 136 | ||
| 5 | 1 | 0.7% | |
| 6 | 9 | 6.6% | |
| 7 | 67 | 49% | |
| 8 | 33 | 24% | |
| 9 | 26 | 19% | |
| PSA value after radical prostatectomy (ng/ml) | 102 | ||
| Mean ± SD | 0.4 ± 1.6 | ||
| Median (range) | 0.04 (0–12) | ||
| PSA value at PET scan (ng/ml) | 175 | ||
| Mean ± SD | 11.1 ± 47.5 | ||
| Median (range) | 1.6 (0.07–429) | ||
| PSA doubling time (months) | 171 | ||
| Mean ± SD | 9.5 ± 10.1 | ||
| Median (range) | 6.7 (0.8–96.9) | ||
| PSA velocity (ng/ml/month) | 171 | ||
| Mean ± SD | 1.6 ± 9.8 | ||
| Median (range) | 0.1 (0–114.5) |
aStandard deviation
bExternal beam radiation therapy